共有 50 笔近期内部人交易记录记录，涉及 Apellis Pharmaceuticals, Inc. (APLS), 包括 17 笔买入 和 30 笔卖出. 内部人买入总额为 $2.58M 内部人卖出总额为 $3.11M.
近期活跃的重要内部人包括 Biogen Inc., Francois Cedric, Dolsten Mikael. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.
内部人交易记录 — APLS
| 日期 |
姓名 |
职位 |
交易类型 |
股数 |
平均价格 |
总价值 |
持股数量 |
| 2026-03-31 |
Biogen Inc. |
Other: See Footnotes |
未知 |
- |
- |
- |
- |
| 2026-03-11 |
Francois Cedric |
Chief Executive Officer |
赠与（收到） |
64,869 |
- |
- |
372,815 |
| 2026-03-02 |
Dolsten Mikael |
Director |
未知 |
- |
- |
- |
- |
| 2026-02-27 |
Dolsten Mikael |
Director |
限制性股票授予 (RSU) |
14,312 |
- |
- |
14,312 |
| 2026-02-11 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
知情卖出 |
368 |
$22.15 |
$8.15K |
114,591 |
| 2026-02-03 |
Francois Cedric |
Chief Executive Officer |
期权行权（卖出） |
8,840 |
$3.76 |
$33.24K |
- |
| 2026-01-28 |
Watson David O. |
General Counsel |
限制性股票授予 (RSU) |
55,986 |
- |
- |
144,517 |
| 2026-01-28 |
Deschatelets Pascal |
Chief Scientific Officer |
限制性股票授予 (RSU) |
25,840 |
- |
- |
1,177,222 |
| 2026-01-28 |
Francois Cedric |
Chief Executive Officer |
限制性股票授予 (RSU) |
195,952 |
- |
- |
481,997 |
| 2026-01-28 |
Sullivan Timothy Eugene |
Chief Financial Officer |
限制性股票授予 (RSU) |
58,140 |
- |
- |
152,041 |
| 2026-01-28 |
Nicholson Nur |
Chief Technical Officer |
限制性股票授予 (RSU) |
45,220 |
- |
- |
116,338 |
| 2026-01-28 |
Chopas James George |
VP/chief Accounting Officer |
限制性股票授予 (RSU) |
16,150 |
- |
- |
65,955 |
| 2026-01-28 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
限制性股票授予 (RSU) |
36,606 |
- |
- |
114,959 |
| 2026-01-28 |
Boucher Kelley |
Chief People Officer |
限制性股票授予 (RSU) |
30,146 |
- |
- |
127,804 |
| 2026-01-28 |
Meltzer Leslie |
Chief Research and Development |
限制性股票授予 (RSU) |
45,220 |
- |
- |
107,024 |
| 2026-01-22 |
Watson David O. |
General Counsel |
知情卖出 |
7,832 |
$21.77 |
$170.47K |
88,531 |
| 2026-01-22 |
Deschatelets Pascal |
Chief Scientific Officer |
知情卖出 |
5,928 |
$21.77 |
$129.03K |
1,151,382 |
| 2026-01-22 |
Francois Cedric |
Chief Executive Officer |
知情卖出 |
27,192 |
$21.77 |
$591.84K |
286,045 |
| 2026-01-22 |
Sullivan Timothy Eugene |
Chief Financial Officer |
知情卖出 |
10,287 |
$21.77 |
$223.9K |
93,901 |
| 2026-01-22 |
Nicholson Nur |
Chief Technical Officer |
知情卖出 |
7,725 |
$21.77 |
$168.14K |
71,118 |
| 2026-01-22 |
Chopas James George |
VP/chief Accounting Officer |
知情卖出 |
2,064 |
$21.77 |
$44.92K |
49,805 |
| 2026-01-22 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
知情卖出 |
3,371 |
$21.77 |
$73.37K |
78,353 |
| 2026-01-22 |
Baumal Caroline |
Chief Medical Officer |
知情卖出 |
2,797 |
$21.77 |
$60.88K |
86,527 |
| 2026-01-20 |
Watson David O. |
General Counsel |
知情卖出 |
2,475 |
$19.79 |
$48.99K |
96,363 |
| 2026-01-20 |
Deschatelets Pascal |
Chief Scientific Officer |
知情卖出 |
909 |
$19.79 |
$17.99K |
1,157,310 |
| 2026-01-20 |
Francois Cedric |
Chief Executive Officer |
知情卖出 |
8,182 |
$19.79 |
$161.95K |
313,237 |
| 2026-01-20 |
Sullivan Timothy Eugene |
Chief Financial Officer |
知情卖出 |
2,892 |
$19.79 |
$57.24K |
104,188 |
| 2026-01-20 |
Nicholson Nur |
Chief Technical Officer |
知情卖出 |
2,203 |
$19.79 |
$43.6K |
78,843 |
| 2026-01-20 |
Chopas James George |
VP/chief Accounting Officer |
知情卖出 |
726 |
$19.79 |
$14.37K |
51,869 |
| 2026-01-20 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
知情卖出 |
1,334 |
$19.79 |
$26.4K |
81,724 |
| 2026-01-20 |
Baumal Caroline |
Chief Medical Officer |
知情卖出 |
1,882 |
$19.79 |
$37.25K |
89,324 |
| 2026-01-13 |
Watson David O. |
General Counsel |
知情卖出 |
5,780 |
$22.19 |
$128.24K |
98,838 |
| 2026-01-13 |
Deschatelets Pascal |
Chief Scientific Officer |
知情卖出 |
2,277 |
$22.19 |
$50.52K |
1,158,219 |
| 2026-01-13 |
Francois Cedric |
Chief Executive Officer |
知情卖出 |
10,186 |
$22.19 |
$226K |
321,419 |
| 2026-01-13 |
Sullivan Timothy Eugene |
Chief Financial Officer |
知情卖出 |
3,856 |
$22.19 |
$85.55K |
107,080 |
| 2026-01-13 |
Nicholson Nur |
Chief Technical Officer |
知情卖出 |
2,618 |
$22.19 |
$58.09K |
81,046 |
| 2026-01-13 |
Chopas James George |
VP/chief Accounting Officer |
知情卖出 |
873 |
$22.19 |
$19.37K |
52,595 |
| 2026-01-13 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
知情卖出 |
1,780 |
$22.19 |
$39.49K |
83,058 |
| 2026-01-07 |
Watson David O. |
General Counsel |
期权行权（卖出） |
888 |
$14.95 |
$13.28K |
14,000 |
| 2026-01-05 |
Baumal Caroline |
Chief Medical Officer |
知情卖出 |
3,020 |
$25.53 |
$77.1K |
91,206 |
| 2026-01-01 |
Wheeler Craig A |
Director |
限制性股票授予 (RSU) |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Machiels Alec |
Director |
限制性股票授予 (RSU) |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Chan Gerald |
Director |
限制性股票授予 (RSU) |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
O'brien Stephanie Monaghan |
Director |
限制性股票授予 (RSU) |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Dunlop A. Sinclair |
Director |
限制性股票授予 (RSU) |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Fonteyne Paul R. |
Director |
限制性股票授予 (RSU) |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Walbert Keli |
Director |
限制性股票授予 (RSU) |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2025-12-16 |
Watson David O. |
General Counsel |
知情卖出 |
5,000 |
$24.49 |
$122.45K |
103,730 |
| 2025-11-17 |
Watson David O. |
General Counsel |
知情卖出 |
5,000 |
$20.06 |
$100.3K |
108,730 |
| 2025-10-21 |
Sullivan Timothy Eugene |
Chief Financial Officer |
知情卖出 |
10,000 |
$28.03 |
$280.3K |
110,936 |
■ 知情交易 — 公开市场买卖（最具参考价值）
■ 非知情买入 — 奖励、期权行权、转换
■ 非知情卖出 — 税务代扣、归属出售
■ 中性 — 礼赠、信托、到期
